This website uses cookies to enhance the user experience.
G

GENO R&D AS993 130 532

Research
Limited company
Storhamargata 44 2317 HAMAR, Norge
Services
/ Research
/ 72.110 Research and experimental development on biotechnology

GENO R&D AS

Keywords

researchdevelopment workbiotechnologygenomicspharmageneticsgene samplesdna sequencingdna synthesisdna deepeninggenetic engineeringproteinsmoleculespeptide sequencinglipidglycotechniqueproteomicshormonesgrowth factorscell receptorspheromonescell culturetissue culturecrossingcell fusionvaccineimmunostimulatorsembryo manipulationprocess biotechnologybioreactorsfermentationbioprocessingbiorecoverybiodesulfurizationbiological pulp productionbiofiltrationbiological regenerationsubcellular organismsgene therapyvirusesvectors

Organization

CEO
HM

Håvard Melbø Tajet1970

Chairman of the board
KM

Kristin Malonæs1970

Years since formation
17 years
since Oct 2, 2008
Type
Limited company
VAT registered
Yes
Number of employees
0

Ownership

Number of shares and share classes
4,500
1 share class
Total number of shareholders
1
company
Belongs to group of

Financials

Total operating income 2024
18,885,066
NOK
Annual total result 2024
164,449
NOK
Total equity 2024
1,766,050
NOK
Last update: Jul 2, 2025

Management

Management / administration

NameRoleShares
HM

Håvard Melbø Tajet

1970

Managing Director/CEO-

Board

NameRoleShares
KM

Kristin Malonæs

1970

Chairman-
LS

Lars Skramstad

1964

Board Member-

Others

NameRoleShares
P
PRICEWATERHOUSECOOPERS AS
Auditor-
Last update: Apr 13, 2023

Ownership

Company shareholders

NameShare classTotal number of sharesShare
G
GENO SA
A-shares
4,500
100 %
Last update: Jun 2, 2025

Group structure

  • GENO SA
    Total operating income 2023: NOK 428,816,000
    Operating profit 2023: NOK 6,730,000
    Employees: 197

Financials

in NOK

Summary

Year2024202320222021
Total operating income
18,885,066
14,917,403
3,100,000
7,280,000
Annual Total Result
164,449
-17,557
14,112
-569,186
Total assets
16,034,513
10,720,182
2,719,620
12,842,719
Total liabilities
14,268,464
9,118,582
1,100,452
11,237,662
Total equity
1,766,050
1,601,600
1,619,168
1,605,057

P&L

Year2024202320222021
Total operating income
18,885,066
14,917,403
3,100,000
7,280,000
Total operating costs
18,941,916
15,056,861
3,122,369
7,297,942
Operating result
-56,850
-139,458
-22,369
-17,942
Financial income/costs
221,299
121,902
36,481
988
Profit before tax
164,449
-17,557
14,112
-16,954
Total tax & extraordinary income/cost
0
0
0
552,232
Annual Total Result
164,449
-17,557
14,112
-569,186

Balance overview

Year2024202320222021
Total fixed assets
0
0
0
0
Total current assets
16,034,513
10,720,182
2,719,620
12,842,718
Total assets
16,034,513
10,720,182
2,719,620
12,842,719
Short term debt
14,268,464
9,118,582
1,100,452
11,237,662
Long term debt
0
0
0
0
Total liabilities
14,268,464
9,118,582
1,100,452
11,237,662
Contributed capital
900,000
900,000
900,000
900,000
Retained earnings
866,050
701,600
719,168
705,057
Total equity
1,766,050
1,601,600
1,619,168
1,605,057
Total equity and liabilities
16,034,513
10,720,182
2,719,620
12,842,719

Classification

Category
Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises
Standard industrial classification
M
Main industrial area
Professional, scientific and technical activities
72
Activity
Scientific research and development
72.1
Main industrial group
Research and experimental development on natural sciences and engineering
72.11
Industrial group
Research and experimental development on biotechnology
72.110
Industrial group
Research and experimental development on biotechnology